Catherine Weiss, PhD

Short- and Long-Term Metabolic Changes in Patients with MDD Treated with Adjunctive Brexpiprazole or Adjunctive Aripiprazole: An Indirect Comparison

Objective: We aimed to describe metabolic changes observed during short- and long-term studies of brexpiprazole and aripiprazole in patients with MDD.

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Peter Zhang , PhD;

Erin MacKenzie , PhD;

Francois Therrien , PharmD;

Ross Baker , PhD, MBA;

11/22/2019

Efficacy of Adjunctive Brexpiprazole in Major Depressive Disorder: A Pooled Response Quartile Analysis

Background: We assessed varying levels of response to brexpiprazole adjunctive to standard antidepressant therapy (ADT).

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Dalei Chen , PhD;

11/22/2019

Predictors of Weight Change After Long-Term Treatment With Brexpiprazole in Schizophrenia

Background: We assessed effects contributing to weight gain during long-term treatment with brexpiprazole.

Mette Josiassen , PhD;

Anders Tvistholm , MS;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Mary Hobart , PhD;

Ross Baker , PhD, MBA;

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019

Symptomatic and Functional Response to Brexpiprazole Treatment in Patients With Acute Schizophrenia by Age

Introduction: The efficacy and safety of brexpiprazole in the treatment of schizophrenia have been demonstrated in short- and long-term studies. This post-hoc analysis assessed the propor...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Peter Zhang , PhD;

Erin MacKenzie , PhD;

Francois Therrien , PharmD;

03/01/2019

Investigating Patient Characteristics as Predictors of Engagement Response to Adjunctive Brexpiprazole in Major Depressive Disorder

Background: Treatment with adjunctive brexpiprazole in major depressive disorder (MDD) has been shown to improve 'patient engagement', a concept related to one‚Äôs energy, interest, and o...

Ross Baker , PhD, MBA;

Jessica Reed , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Dalei Chen , PhD;

10/08/2020

The Impact of Second-Generation Antipsychotic Medication Side-Effects on Functioning From a Schizophrenia Patient Perspective: a Cross-Sectional, Observational, Patient Centered, Web Survey Study

Background: Second-generation antipsychotics (SGAs) are associated with well-known side effects (SEs). We aimed to gain a patients’ perspective on how specific SEs impact daily functionin...

William Lenderking , PhD;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Ann Hartry , PhD;

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Owen Cooper , MSc;

Leah Kleinman , DrPH;

Randall Bender , PhD;

Rajiv Tandon , MD;

03/01/2019

Patient-Reported Effects of Adjunctive Brexpiprazole on Calming and Engagement in Major Depressive Disorder: Post Hoc Analysis of Clinical Trial Exit Interviews

Background: Calming patients (without sedation) and increasing engagement (without overactivation) are important components of the successful treatment of major depressive disorder (MDD)....

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Catherine Gupta , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

T. Michelle Brown , PhD;

10/08/2020

Efficacy and Safety of Brexpiprazole in Patients With Schizophrenia Presenting With Severe Psychotic Symptoms During an Acute Exacerbation

Background: Schizophrenia is a chronic, disabling and progressive disease, with heterogenous symptoms and disease course between individuals. Severity of symptoms has been shown to be a s...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Nicole Meade , PhD;

Lily Shi , MSc;

03/01/2019

Examining Depressive Symptoms Across Diagnostic and Statistical Manual Indications: Treatment Effects of Brexpiprazole in Patients With Major Depressive Disorder and Schizophrenia

Background: The NIMH Research Domain Criteria (RDoC) framework could be used to recategorize symptoms across the established DSM criteria for neuropsychiatric disorder indications. This p...

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

Malaak Brubaker , PhD;

Dalei Chen , PhD;

Ross Baker , PhD, MBA;

Ruth Duffy , PhD;

10/08/2020